Abstract Alzheimer's disease (AD) is a neurodegenerative disorder causing progressive memory loss and cognitive dysfunction. Anti-AD strategies targeting cell receptors consider them as isolated units. However, many cell surface receptors cooperate and physically contact each other forming complexes having different biochemical properties than individual receptors. We here report the discovery of dopamine D 1 , histamine H 3 , and N-methyl-D-aspartate (NMDA) glutamate receptor heteromers in heterologous systems and in rodent brain cortex. Heteromers were detected by co-immunoprecipitation and in situ proximity ligation assays (PLA) in the rat cortex where H 3 receptor agonists, via negative cross-talk, and H 3 receptor antagonists, via cross-antagonism, decreased D 1 receptor agonist signaling determined by ERK1/2 or Akt phosphorylation, and counteracted D 1 receptor-mediated excitotoxic cell death. Both D 1 and H 3 receptor antagonists also counteracted NMDA toxicity suggesting a complex interaction between NMDA receptors and D 1 -H 3 receptor heteromer function. Likely due to heteromerization, H 3 receptors act as allosteric regulator for D 1 and NMDA receptors. By bioluminescence resonance energy transfer (BRET), we demonstrated that D 1 or H 3 receptors form heteromers with NR1A/ NR2B NMDA receptor subunits. D 1 -H 3 -NMDA receptor complexes were confirmed by BRET combined with fluorescence complementation. The endogenous expression of complexes in mouse cortex was determined by PLA and similar expression was observed in wild-type and APP/PS1 mice. Consistent with allosteric receptor-receptor interactions within the complex, H 3 receptor antagonists reduced NMDA or D 1 receptor-mediated excitotoxic cell death in cortical organotypic cultures. Moreover, H 3 receptor antagonists reverted the toxicity induced by ß 1-42 -amyloid peptide. Thus, histamine H 3 receptors in D 1 -H 3 -NMDA heteroreceptor complexes arise as promising targets to prevent neurodegeneration.
Introduction
Current Alzheimer's disease (AD) therapies mainly target acetyl cholinesterase to enhance cholinergic neurotransmission. However, neurodegeneration is not limited to a specific neurotransmitter system. Glutamatergic, serotonergic, adrenergic, dopaminergic, and peptidergic neurotransmitter systems are also deregulated in AD [1] . Impaired neuronal signaling may affect amyloid precursor protein (APP) proteolysis and promote amyloid formation in the AD brain. In addition, amyloid toxicity and neurodegeneration may affect neurotransmission, suggesting the involvement of complex positivefeedback loops in the pathogenesis of the disease. Consequently, a complementary approach that includes modulation of neurotransmission in addition to lowering the amyloid burden is an attractive therapeutic strategy for the treatment of AD [1] [2] [3] . Indeed, activation of dopamine D 1 -like receptors protects neurons from synapse dysfunction induced by amyloid oligomers [4] and we and others have shown that dopamine facilitates hippocampal acetyl-choline release by acting on D 1 -like receptors that are G protein-coupled receptors (GPCR) located in hippocampal cholinergic terminals [5] [6] [7] [8] . Moreover, activation of dopamine D 1 receptors (D 1 R) enables working memory by enhancing the firing of pyramidal neurons [9, 10] . Thus, the dopaminergic system is a key neurotransmitter system involved in AD. Another key neurotransmitter system implicated in AD is the histaminergic system [11] [12] [13] [14] [15] and GPCR histamine H3 receptors (H 3 R) are widely expressed in the CNS, particularly in the frontal cortex and hippocampus [16] . H 3 R antagonists are promising drugs for AD [17] [18] [19] but the exact mode of action is more complex than suspected. One potential mechanism may be the blockade of histamine receptors in a specific CNS heterooligomeric context. Indeed, hetero-oligomerization of proteins is a recurrent phenomenon in biology [20, 21] . Dopamine D 1 GPCRs interact in striatum with inter alia the histamine H 3 receptor. Whereas D 1 receptors are coupled to heterotrimeric G s proteins and histamine H 3 receptors couple to G i /G o , D 1 /H 3 receptor heteromers (D 1 /H 3 RHets) allow histamine H 3 receptor agonists to activate the mitogen-activated protein kinase (MAPK) pathway. The link between histamine receptors and MAPK depends on heteromer formation as it does not happen in D 1 receptor-deficient mice [6, 22] .
In the case of ionotropic glutamate receptors, formation of hetero-oligomers is needed for proper function. In transfected cells, N-methyl-D-aspartate (NMDA) regulates dopamine D 1 receptor trafficking and desensitization by a direct interaction between the ionotropic glutamate (NMDA) and the metabotropic dopamine (D 1 ) receptors [23] . Lee et al. (2002) showed, also in an heterologous system, that the cytoplasmic tail of the D 1 receptor has two epitopes to interact with NR1-1a and NR2A subunits of the NMDA receptor [24, 25] . The interaction with NR1-1a affects NMDA receptor-mediated excitotoxicity while the interaction with NR2A affects ligand-gated currents. Besides inhibitors of acetyl cholinesterase, the only drug approved for Alzheimer's disease is Namendal R whose active component, memantine, is an allosteric modulator of NMDA receptors [26] , which remain one of the main therapeutic targets in this neurodegenerative disease [27] . As heteroreceptor complexes formed by different GPCRs [28] or by combination of GPCR and ionotropic receptors [29] have specific physiological functions and emerge as novel therapeutic targets, the aim of the present paper was to look for heteromers formed by dopamine D 1 , histamine H 3 , and NMDA receptors and to assess their potential as targets in Alzheimer's disease.
Materials and Methods

Animals
Two-month-old male Sprague Dawley rats (animal facility of the Faculty of Biology, University of Barcelona) were housed two per cage and kept on a 12/12-h dark/light cycle with food and water available ad libitum and experiments were performed during the light cycle. Animals were anesthetized with 4 % isoflurane and euthanized by decapitation. APP/PS1 mice and wild-type (WT) littermates were used. The generation of mice expressing the human mutated forms of the amyloid precursor protein (APPswe) and presenilin-1 (PS1dE9) is described elsewhere [3] . In the present study, identification of transgenic mice was carried out as follows: genomic DNAwas isolated from 1-cm tail clips and genotyped by polymerase chain reaction (PCR) technique using the PCR conditions proposed by the Jackson Laboratory (www.jax.org). Animals were maintained under standard animal housing conditions in a 12-h dark-light cycle with free access to food and water. Animal procedures were conducted according to ethical guidelines (European Communities Council Directive 2010/63/EU) and approved by the animal experimentation ethics committee of the Catalan Government (CEEA-DAAM 6419 and CEEA/DMAH 4049 and 5664).
Co-Immunoprecipitation Experiments
Rat cortical tissue was homogenized at 4°C in 50 mM TrisHCl buffer, pH 7.4, containing a protease inhibitor mixture (1/ 1000, Sigma-Aldrich, St. Louis, MO, USA) using a Polytron homogenizer, and membranes were obtained by centrifugation at 105,000g for 1 h at 4°C. Membranes were washed three more times at the same conditions and were solubilized by homogenization in ice-cold immunoprecipitation buffer (phosphate-buffered saline, pH 7.4, containing 1 % (v/v) Nonidet P-40) and incubated for 30 min on ice before centrifugation at 105,000g for 1 h at 4°C. Using a Dynabeads® Protein G kit (Invitrogen, Paisley, Scotland, UK), the supernatant (1 mg/ml of protein) was processed as described in the immunoprecipitation protocol. Protein content was quantified by the bicinchoninic acid method (Pierce) using bovine serum albumin dilutions as standard. Immunoprecipitation was carried out with a rat anti-D 1 receptor antibody (1:1000, SigmaAldrich). As negative control, anti-calnexin antibody was used (1:1000, BD Biosciences Pharmingen, San Diego, CA, USA). Immunoprecipitates were separated on a denaturing 10 % SDS-polyacrylamide gel and transferred onto PVDF membranes to perform western blot assays. Membranes were probed with guinea pig anti-D 1 receptor (1:1000, Frontier Institute, Ishikari, Hokkaido, Japan) and rabbit anti-H 3 receptor (1:1000, Alpha diagnostic, San Antonio, Texas, USA) antibodies and the appropriate secondary antibodies: goat antiguinea pig-peroxidase (1:20,000, Sigma-Aldrich) and goat anti-rabbit-peroxidase (1:20,000, Thermo Scientific, Fremont, CA). Bands were visualized with a LAS-3000 equipment (Fujifilm). Data analysis was performed by Image Gauge software (version 4.0) and Multi Gauge software (version 3.0).
Preparation of Rat and Mouse Brain Sections and Slices
For PLA experiments, rat and mouse brains were rapidly removed and fixed with 4 % paraformaldehyde solution for 24 h at 4°C. Brains were then washed in PBS, cryo-preserved in a 30 % sucrose solution for 48 h at 4°C, and stored at −20°C until sectioning. Cortical 15-μm thick sections were cut on a freezing cryostat (Leica Jung CM-3000, Leica Microsystems, Mannheim, Germany) and mounted on glass slides. For cell death determination and signaling experiments, the brains were rapidly removed and placed in ice-cold oxygenated (O 2 /CO 2 : 95/5 %) Krebs-bicarbonate buffer (in millimolars: 124 NaCl, 4 KCl, 1.25 KH 2 PO 4 , 1.5 MgCl 2 , 1.5 CaCl 2 , 10 glucose, and 26 NaHCO 3 ) pH 7.4. The brains were sliced along the coronal plane at 4°C using a brain matrix (Zivic Instruments, Pittsburgh, PA, USA). Cortical slices (500 μm thick) were kept at 4°C in Krebs-bicarbonate buffer during the dissection.
Cell Culture, Expression Vectors and Transient Transfection
Human embryonic kidney (HEK-293 T) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine, 100 μg/ml sodium pyruvate, 100 units/milliliter penicillin/streptomycin, MEM non-essential amino acid solution (1/100), and 5 % (v/v) heat-inactivated fetal bovine serum (FBS) (all supplements were from Invitrogen). For transfection, sequences encoding receptors or fusion proteins consisting of the human receptors fused to Renilla luciferase (Rluc) or to yellow fluorescent protein (YFP) on the C-terminal end of the receptor (D 1 R-YFP, H 3 R-YFP, CB 1 R-Rluc), of human (H 3 , D 1 , and CB 1 ) receptors fused to the YFP Venus N-terminal fragment (n-YFP), or of human (serotonin 5-HT 2B , H 3 , and D 1 ) fused to the YFP Venus C-terminal fragment (c-YFP) were obtained and characterized as previously described (Navarro et al. 2008 ; [6, 7, 31, 32] .
Plasmids encoding human NR1A-Rluc and NR2B were generously provided by Dr. Julie Perroy from the University of Montpellier (France). HEK-293 T cells growing in 35-mm diameter six-well plates were transiently transfected with cDNAs by the ramified polyethylenimine (PEI; SigmaAldrich) method. Cells were incubated (4 h) with cDNAs, ramified PEI (5 ml/mg cDNA of 10 mM PEI) and 150 mM NaCl in a serum-free medium. After 4 h, the medium was changed to a fresh complete culture medium. Forty-eight hours after transfection, cells were washed twice in quick succession in HBSS containing the following (in millimolars): 137 NaCl, 4 , supplemented with 0.1 % glucose (w/v), detached by gently pipetting, and resuspended in the same buffer. To control the cell number, sample protein concentration was determined using a Bradford assay kit (Bio-Rad) using bovine serum albumin (BSA) dilutions as standards. HEK-293 T cell suspension (20 μg of protein) was distributed into 96-well microplates; black plates with a transparent bottom (Porvair, King's Lynn, UK) were used for fluorescence determinations, whereas white opaque plates (Sigma-Aldrich) were used for bioluminescence resonance energy transfer (BRET) experiments.
Fluorescence Complementation Assays
HEK-293 T cells were transiently co-transfected with the cDNA encoding for H 3 , D 1 , or CB 1 receptors fused to the YFP Venus N-terminal fragment (n-YFP) and 5-HT 2B , H 3 , or D 1 receptors fused to the YFP Venus C-terminal fragment (c-YFP). To quantify the amount of reconstituted YFP Venus, cells (20 μg protein) were distributed in 96-well plates (black plates with a transparent bottom, Porvair), and emission fluorescence at 530 nm was read in a FluoStar Optima plate fluorometer (BMG Labtechnologies, Ortenberg, Germany) equipped with a high-energy xenon flash lamp, using a 10-nm bandwidth excitation filter at a 400-nm reading. Protein fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells not expressing the fusion proteins (basal). Cells expressing two receptorcYFP or two receptor-nYFP fusion proteins showed similar fluorescence levels to non-transfected cells.
BRET and BRET with Bimolecular Fluorescence Complementation
HEK293 T cells were transiently co-transfected with a constant amount of cDNA encoding for the receptor fused to Rluc and with increasing amounts of cDNA for the receptor fused to YFP (see figure legends). To quantify receptor-YFP expression, fluorescence of cells (20 μg protein) was read in a FluoStar Optima Microplate Fluorometer (BMG Labtechnologies) equipped with a high-energy xenon flash lamp, using a 10-nm bandwidth excitation filter at 400 nm reading. For bioluminescent resonance energy transfer (BRET) or BRET with bimolecular fluorescence complementation (BiFC) measurements, 5 μM coelenterazine H (Invitrogen) was added to the equivalent of 20 μg of cell suspension. After adding coelenterazine H (1 min for BRET or 5 min for BRET with BiFC), readings were collected using a Mithras LB 940 that allows the integration of the signals detected in the short-wavelength filter at 485 nm (440-500 nm) and the long-wavelength filter at 530 nm (510-590 nm). To quantify receptor-Rluc expression, luminescence readings were also performed after 10 min of adding 5 μM coelenterazine H. The net BRET is defined as [(long-wavelength emission)/(short-wavelength emission)]−cf., where cf. corresponds to [(long-wavelength emission)/(short-wavelength emission)] for the donor construct expressed alone in the same experiment. Data were fitted to a nonlinear regression equation, assuming a single-phase saturation curve with GraphPad Prism software. BRET is expressed as milliBRET units (mBU).
Determination of Phospho-Extracellular-Signal Regulated Kinase (ERK1/2) and Phospho-Akt/Protein Kinase B (PKB)
After dissection, fresh cortical slices were transferred into 1 ml of ice-cold Krebs-bicarbonate buffer. The temperature was raised to 23°C and after 30 min, the culture medium was replaced by 2 ml of fresh Krebs-bicarbonate buffer (23°C). Slices were incubated under constant oxygenation (O 2 /CO 2 : 95 %/5 %) at 30°C for 4-5 h in an Eppendorf thermomixer (5 Prime, Inc., Boulder, CO, USA). The medium was replaced by 200 μl of fresh Krebs-bicarbonate buffer and incubated for 30 min before the addition of any agent. Slices were treated with the indicated ligand concentration for the indicated time and lysed with (in millimolars) 50 Tris-HCl pH 7.4, 50 NaF, 150 NaCl, 45 mM glycerol-3-phosphate, 0.02 phenyl-arsine oxide, 0.4 NaVO 4 , and 1 % Triton X-100 and protease inhibitor cocktail. Cellular debris was removed by centrifugation at 13,000g for 10 min at 4°C and total protein was quantified by the bicinchoninic acid method using bovine serum albumin dilutions as standard. To determine the degree of protein phosphorylation, equivalent amounts of protein were separated by electrophoresis on a denaturing 10 % SDS-polyacrylamide gel and transferred onto PVDF-FL membranes. Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) was then added, and the membrane was rocked for 90 min. The membranes were then probed overnight with a mixture of a mouse anti-phospho-ERK1/2 antibody (1:2500; Sigma-Aldrich), a rabbit anti-phospho-Ser473-Akt antibody (1/2500, SAB Signalway Antibody, Pearland, Texas, USA), and a rabbit anti-ERK1/2 antibody that recognizes both phosphorylated and unphosphorylated ERK1/2 (1:40,000; Sigma-Aldrich). The 42-and 44-kDa bands corresponding to ERK1 and ERK2 were visualized by the addition of a mixture of IRDye 800 (anti-mouse) antibody (1:10,000; Sigma-Aldrich) and IRDye 680 (anti-rabbit) antibody (1:10,000; SigmaAldrich) for 2 h and scanned by the Odyssey infrared scanner (LI-COR Biosciences). Band densities were quantified using the scanner software and exported to Excel (Microsoft, Redmond, WA, USA). The level of phosphorylated ERK1/2 isoforms or of pAkt/PKB was normalized for differences in loading using the total ERK1/2 protein band intensities.
Cell Death Determination in Rat and Mouse Organotypic Cultures
Immediately after dissection, brain slices (500 μm thickness, see above) were placed in six-well plates containing Millicell-CM organotypic tissue culture plate inserts (EMD Millipore Corporation, Billerica, MA, USA) and cultured at 37°C with Neurobasal medium supplemented with 20 % horse serum, 0.5 % B27, 2 mM L-glutamine, 100 μg/ml sodium pyruvate, MEM non-essential amino acid solution (1/100), and 100 units/milliliter penicillin/streptomycin (all supplements were from Invitrogen). After 24 h, culture medium was replaced by fresh medium containing no ligands or the indicated concentrations of SKF-81297, SCH-23390, NMDA, MK-801, or thioperamide 1 h before the addition of the excitotoxic agents (D 1 or NMDA receptor agonists at 50 μM). Slices were maintained 48 h more in culture and, after a total 72 h of incubation, 10 μM propidium iodide (PI) was added to culture medium, which was maintained at 37°C for 1 h. Slices were then removed from the incubator, washed twice in cold-PBS and fixed with 4 % paraformaldehyde for 1 h at 4°C. Nuclei were stained with 1:1000 Hoechst for 1 h. Total (Hoechst-stained) and PI-positive nuclei were quantified to evaluate cell death using Leica SP2 confocal microscope (20×; UV, 561 lasers) and the quantification program Image-based Tool for Counting Nuclei for ImageJ.
In Situ Proximity Ligation Assays (PLA)
Rat or mouse cortical brain sections were mounted on glass slides, thawed at 4°C, washed in 50 mM Tris-HCl, 0.9 % NaCl pH 7.8 buffer (TBS), permeabilized with TBS containing 0.01 % Triton X-100 for 10 min, and repeatedly washed with TBS. Heteromers were detected using the Duolink II in situ proximity ligation assays (PLA) detection Kit (SigmaAldrich) following the instructions of the supplier. To detect D 1 -H 3 , NMDA/NR1-D 1 , or NMDA/NR1-H 3 heteroreceptor complexes, we used a mixture of equal amounts of the following pairs of primary antibodies: (i) guinea pig anti-D 1 receptor (Frontier Institute, Hokkaido, Japan) and rabbit anti-H 3 (Alpha diagnostic) receptors, (ii) guinea pig anti-D 1 and rabbit anti-NMDA/NR1 (Abcam Inc., Cambridge, MA, USA) antibodies, or (iii) rabbit anti-NMDA/NR1 antibody directly coupled to a minus DNA chain and rabbit anti-H 3 receptor antibody directly coupled to a plus DNA chain (obtained following the instructions of the Sigma-Aldrich supplier). PLA probes detecting guinea pig or rabbit antibodies were used to detect D 1 -H 3 and NMDA/NR1-D 1 receptor complexes. Then samples were processed for ligation and amplification and were mounted using a DAPI-containing mounting medium. Samples were observed in a Leica SP2 confocal microscope equipped with an apochromatic 63X oil-immersion objective (N.A. 1.4), and a 405-nm and a 561-nm laser lines. For each field of view a stack of two channels (one per staining) and six to seven Z stacks with a step size of 1 μm were acquired. Quantification of cells containing one or more red spots versus total cells (blue nucleus) and, in cells containing spots, the ratio r (number of red spots/cell) were determined, using the Fiji package (http://pacific.mpi-cbg.de/), considering a total 1000-2000 cells from 7 to 16 different fields from three different animals. Nuclei and red spots were counted on the maximum projections of each image stack. After getting the projection each channel was processed individually. The nuclei were segmented by filtering with a median filter, subtracting the background, enhancing the contrast with the Contrast Limited Adaptive Histogram Equalization (CLAHE) plug-in, and finally applying a threshold to obtain the binary image and the regions of interest (ROI) around each nucleus. Red spot images were also filtered and thresholded to obtain the binary images. Red spots were counted in each of the ROIs obtained in the nuclei images. The number of red dots after PLA was negligible in the negative controls constituted by sections only incubated with one primary antibody (anti-D 1 R in rat and mouse slices and anti-H 3 R in mouse slices).
Statistical Analysis
The data in the graphs are presented as the mean ± SEM. Statistical analysis was performed with SPSS 18.0 software. The test of Kolmogorov-Smirnov with the correction of Lilliefors was used to evaluate the fit of the data to a normal distribution and the test of Levene to evaluate the homogeneity of variance. Significance was analyzed by two-way or oneway ANOVA followed by post hoc Bonferroni's test (see figure legends) for multiple comparisons. Significant differences were considered when p < 0.05.
Results
Identification of Heteromers in Brain Cortex
D 1 /H 3 heteroreceptor complexes (D 1 /H 3 RHets) have been described in the striatum [22] . In an attempt to identify D 1 / H 3 RHets in the cerebral cortex, co-immunoprecipitation and in situ proximity ligation assays (PLA) were performed in rat samples. Detergent extracts from rat cortex were immunoprecipitated with antibodies against D 1 receptors and immunoblotted using either anti-D 1 or anti H 3 -receptor antibodies. Results depicted in Fig. 1a -c indicate that immunoprecipitates contained both receptors. The in situ proximity ligation assay (PLA), which allows detection of proteins in close proximity, confirmed in cortical sections that D 1 and H 3 receptors form aggregates, detected as red dots in some of the neural cells (Fig. 1d) . The number of red dots after PLA was negligible in the negative controls constituted by sections only incubated with one primary antibody (anti-D 1 receptor antibody; Fig. 1e) .
As previously reported, D 1 /H 3 RHets may couple to the MAP kinase pathway [22] . Slices from rat cortex were incubated (8 min) with agonists, and ERK1/2 and Akt phosphorylation were assayed. Activation of D 1 (Fig. 2a) . Fairly similar results were obtained on analyzing pAkt data (Fig. 2b) . Such cross-antagonism is one common feature of receptor heteromers that may be considered as a D 1 / H 3 RHet print.
Since previous reports from different laboratories [23, 24] have described the in vitro interaction between the NR1A subunit of NMDA receptor and D 1 receptors, we investigated by PLA whether aggregates formed by NMDA and D 1 receptors or NMDA and H 3 receptors could be detected in sections from rat cortex. PLA experiments were performed in rat cortical sections using antibodies specific for the two GPCRs and for the NR1A subunit. PLA data indicated the existence of NR1A-D 1 or NR1A-H 3 receptors in close proximity (Fig. 3a, b) . Very few red dots were found in negative controls performed with primary antibodies against D 1 , Fig. 1e The next aim was to establish whether D 1 , H 3 , and NMDA receptors could form heteromeric complexes in heterologous cells expressing the three receptors. To attempt to identify the formation of direct interactions involving these receptors, a combination of bioluminescence resonance energy transfer (BRET) and bimolecular fluorescence complementation (BiFC) was undertaken [30] . HEK-293 T cells were transfected with cDNAs encoding for fusion proteins formed by Rluc or YFP and the whole open reading frame of D 1 , H 3 , or the NR1A subunit of NMDA receptors. Cells expressing the NR1A subunit fused to Rluc and D 1 R-YFP provided a saturable BRET signal that proves the interaction between the two proteins (Fig. 4b) . BRET 50 was 7.0 ± 0.7 mBU and BRET max was 51 ± 2 mBU (mean ± SD; n = 3-6). As the NR2B subunit is needed for surface expression of NMDA receptors, the experiment was repeated in cells expressing NR1A and NR2B subunits. BRET signal was saturable indicating that NR1A-Rluc does interact with D 1 -YFP even in the presence of the third protein (Fig. 4c) . BRET 50 was 20 ± 10 mBU and BRET max was 70 ± 20 mBU (mean ± SD; n = 3-6). Different BRET 50 values in the absence and presence of NR2B subunit indicate that the hetero-oligomer forms with a different affinity. BRET data using H 3 and NMDA receptors were qualitatively different. On the one hand, the NR1A-Rluc subunit did not provide specific BRET readouts when transfected with H 3 -YFP receptors, i.e., the relationship with the acceptor/donor ratio was linear, thus suggesting a lack of interaction (Fig. 4d) . On the other hand, BRET between NR1A-Rluc and H 3 -YFP converted into saturable when the NR2B subunit was co-expressed (Fig. 4e) . Taken together, data indicate that H 3 and D 1 receptors may form a complex with functional NR1A/NR2B NMDA receptors. Importantly, evidence for complexes having the three receptors was obtained by the dopamine-induced increase of BRET max between NR1A-Rluc and H 3 -YFP (in the presence of D 1 and NR2B) (Fig. 4f) . To know whether a macromolecular complex may include the four proteins, a BRET with bimolecular fluorescence complementation assay was performed. For complementation experiments, different ratios of plasmids encoding fusion proteins constituted by H 3 or D 1 receptors and one half of the YFP (H 3 R-nYFP and D 1 R-cYFP) were assayed to optimize fluorescence emission after complementation (ESM 1: Fig. S1a, b) . The optimal cDNA ratio was 1.5 and 4 μg for, respectively, plasmids coding H 3 R-nYFP or D 1 R-cYFP (ESM 1: Fig. S1 ). The assayed negative controls were those constituted by non interacting pairs: serotonin 5HT 2B and H 3 receptors fused to, respectively, the C-terminal and N-terminal hemi-domains of YFP, or cannabinoid CB 1 and D 1 receptor fused to, respectively, the N-terminal and C-terminal hemi-domains of YFP (ESM 1: Fig. S1 ). Cells were then transfected with cDNAs encoding for NR1A-Rluc, NR2B, and H 3 and D 1 receptors fused to, respectively, the Nterminal and C-ter minal hemi -domains of YFP. Complementation was confirmed by a saturable BRET signal (Fig. 4h) , thus demonstrating the formation of a macromolecular complex containing D 1 , H 3 , and NMDA receptors. The negative control in cells co-expressing CB 1 R-Rluc, D 1 RcYFP, and H 3 R-nYFP led to a linear non-specific BRET reflecting the inability of the cannabinoid CB 1 receptor to interact with D 1 /H 3 RHets (Fig. 4h) .
In Vitro Neuroprotection
The effect on NMDA-mediated excitotoxicity of D 1 and H 3 receptor ligands was tested in slices from rat cortex. Images comparing Hoechst and propidium iodide labeling are shown in Fig. 5 (top) . Quantification of dead versus total cells showed that NMDA but also SKF-81297, a full D 1 receptor agonist, were able to significantly induce cell death (Fig. 5,  bottom) . A selective NMDA antagonist, MK-801, partially reversed the SKF-81297-induced toxicity. The D 1 receptor selective antagonist, SCH-23390, and, interestingly, the selective H 3 receptor antagonist, thioperamide, were able to markedly reduce the toxicity induced by NMDA (Fig. 5, bottom) .
Similar experiments were performed in slices from a transgenic model of Alzheimer's disease, namely the APP/PS1 mouse. Brain cortical slices from APP/PS1 and age-matched non-transgenic (wild-type) animals were treated with NMDA or SKF-81297 to provoke excitotoxic neuronal cell death. The two drugs led to a significant cell death in samples from the two animal groups that was prevented by 10 μM MK-810, the selective NMDA receptor antagonist. The antihistamine drug (10 μM thioperamide) also led to a significant prevention of excitotoxic damage. Neuroprotection was also afforded by thioperamide in samples from APP/PS1 animals treated with SKF-81297. In addition, the D 1 receptor selective antagonist SCH-23390 also counteracted the death induced by NMDA (Fig. 6a, b) . Overall, neuroprotection data show the interplay between the three receptors and that antagonists may prevent excitotoxic neuronal death.
Expression of Heteromers in Cortex from APP/PS1 Mice
Unfortunately, there is not any reliable methodology to detect three interacting proteins in natural sources. Thus, the potential expression of macromolecular complexes in cortex was addressed by PLA assays aimed at detecting heteromers between pairs of proteins. Using combinations of antibodies, macromolecular complex expression was assayed in the cortex of wild-type and APP/PS1 mice, which exhibit an accelerated AD phenotype due to overexpression of the human amyloid precursor protein harboring the Swedish double mutation and of the presenilin-1 L166P mutant. Red dots reflecting positive PLA were observed in samples treated with antibodies against D 1 and H 3 receptors, with antibodies against D 1 and NR1A receptors and with antibodies against H 3 and NR1A. The number of red dots after PLA was negligible in the negative controls, obtained by doing the PLA experiments in wild-type and APP/PS1 mice brain sections only incubated with antibodies against D 1 (Fig. 7a, b) or against H 3 receptors (not shown). In cortical sections from wild-type mice, the percentage of cells expressing D 1 -H 3 , NMDA/ NR1A-D 1 , or NMDA/NR1A-H 3 complexes was similar; also similar were the dots/cell ratios (Fig. 7b, black bars) . Although indirect, these PLA results constitute evidence that the three receptors form a macromolecular complex. The percentage of dimer-expressing cells was also similar in the cortex from the APP/PS1 mouse (Fig. 7b left, red bars) also suggesting the occurrence in the cortex of APP/ Fig. 2 a, b Signaling cross-talk and cross-antagonism on ERK 1/2 and Akt phosphorylation in rat cortical slices. Slices were preincubated with Krebs-bicarbonate buffer with/without antagonists (10 μM thioperamide or 10 μM SCH-23390) for 20 min prior to the addition of agonists (1 μM SKF-81297), followed by a further incubation of 10 min. ERK1/2 or Akt phosphorylation was determined as described in BMaterials and Methods.^For each treatment, immunoreactive bands from eight slices obtained in two different experiments from a total of ten animals were quantified, and values represent the mean ± SEM of the percentage of phosphorylation relative to basal levels found in untreated slices (100 %). Significant differences were calculated by one-way ANOVA with post hoc Bonferroni's test for multiple comparisons (***p < 0.001 compared with the control condition; experiments were carried out 48 h post-transfection using 0.05 μg of cDNA for NR1A-Rluc and to NR2B (or 0.08 μg of cDNA for CB 1 RRluc) and increasing amounts of cDNA for H 3 R-nYFP (0.5-6 μg cDNA) and D 1 R-cYFP (0.5-3 μg cDNA). Both fluorescence and luminescence of each sample were measured in every experiment to confirm similar donor expressions (∼130,000 bioluminescence units) while monitoring the increase in acceptor expression (10,000-40,000 fluorescence units in BRET saturation experiments and 10,000-25,000 fluorescence units in BiFC experiments). The relative amount of BRET is given as a function of 100 × the ratio between the fluorescence of the acceptor (YFP) and donor (Rluc) expression. BRET and BiFC are expressed as milliBRET units (mBU) and values are the mean ± SEM from four to ten different experiments grouped as a function of the amount of acceptor PS1 animals of complexes formed by the two GPCRs and the NR1A subunit of the NMDA receptor. Differences in the labeling of the three different pair of proteins between wild-type and APP/PS1 animals were statistically significant but small in magnitude (circa 10 %). Thus, it may be assumed that the differences in the expression of complexes formed by the three proteins are low. Looking at red spots/cell ratios, the highest change in transgenic versus wilt-type animals is the expression of dimers formed by H 3 receptors and the NR1A subunit. Such increase correlated with a small increase in the ratio of D 1 -NR1A pairs and a small increase in the ratio of H 3 -NR1A pairs (Fig. 7b, right panel) . These results highlight the occurrence in the cortex of the AD mouse of pairs of proteins, and allegedly of complexes of the three receptors, at levels comparable to those found in samples from wildtype animals. Due to the relevance of Aß peptide toxicity in Alzheimer's disease pathophysiology, we assayed whether the H 3 receptor antagonist could be neuroprotective against the toxic action of Aß. Images comparing Hoechst and propidium iodide labeling are shown in Fig. 8 (top) , and the results showed that 10 μM thioperamide was totally effective in blocking the toxic effect of 1 μM Aß 1-42 peptide (Fig. 8, bottom) . Similar effects were obtained with other selective H 3 receptor antagonists (not shown). Our results suggest heterooligomer formation in cortex from wild-type and APP/ PS1 animals and show that antagonists of dopamine or of histamine receptors consistently afford neuroprotection against excitotoxic agents or Aß 1-42 peptide.
Discussion
Dopamine and NMDA receptor interactions have potential from a therapeutic point of view. A main issue on targeting post-synaptic receptors with agonist or antagonists is the alteration of important neural functions (reviewed in [25] ). Activation of D 1 and NMDA receptors converge in the ERK1/2 MAP kinase cascade [33] . pERKs translocate to the Neural cell toxicity by dopamine is mediated by both cell surface receptors [34, 35] and by intracellular metabolism leading to increased NAD(P) + /NAD(P)H ratios (Giménez-Xavier et al. [36] and references therein, [37] ). Toxic mechanisms include a dopamine-induced increase in cytosolic SULT1A1/3 sulfotransferase levels, the enzyme that metabolizes the neurotransmitter to dopaminesulfate. Induction of sulfotransferases is preceded by dopamine-receptor-mediated ERK phosphorylation and inhibited by the D 1 receptor antagonist SCH-23390. Interestingly, induction of SULT1A1/3 requires NMDA receptor signaling thus suggesting a dopamine D 1 -NMDA receptor-mediated mechanism [37] .
The quaternary structure of receptor complexes is key for signaling to the MAP kinase cascade [38] . The NR1A and NR2A subunits of the NMDA receptor interact with two regions in the carboxyl tail of the D 1 receptor. Interestingly, one interaction is involved in modulating receptor-gated currents and the other in the attenuation of NMDA receptor-mediated excitotoxicity [24] . Our results suggest the formation of heteromers formed by D 1 , H 3 , and NR1A-NR2B NMDA receptors in which the quaternary structure of the complex allows close contacts between D 1 and H 3 receptors and the two NMDA receptor subunits. PLA studies in cortical sections from rats and mice, including the APP/PS1 transgenic line, showed aggregates formed by NMDA, D 1 and/or H 3 receptors that are suggestive of complexes formed by the three receptors. Indeed, in vitro assays using BRET and bimolecular fluorescence complementation constitute evidence of complexes containing D 1 , H 3 , and NR1A-NR2B NMDA receptors. Dopamine-induced increase of BRET max between NR1A-Rluc and H 3 -YFP (in the presence of the NR2B subunit and the D 1 receptor) reflects the allosteric interactions expected when one receptor within the hetero-oligomer is activated. Alteration of the quaternary structure of the overall macromolecular complex by H 3 receptor antagonists seems to uncouple the death program induced by engagement of D 1 or NMDA receptors (Fig. 9) . The protection afforded in rat cortical slices by the H 3 receptor antagonist, thioperamide, was virtually complete. It is worth noting that thioperamide in cortical slices from APP/PS1 mice reverted the excitotoxic shock. Although not statistically significant, there was a tendency of thioperamide decreasing the degree of death in APP/PS1 slices incubated with medium lacking any added compound. The neuroprotection exerted by thioperamide in wild-type and APP/PS1 mice was very similar, being this result consistent with the similar level of expression of D 1 /H 3 , D 1 /NR1A, or H3/NR1A pairs of proteins in the cerebral cortex from both animal groups. Assessment of the degree of expression of complexes formed by the three (D 1 , H 3 , and NMDA) receptors cannot be direct. Hence, extrapolating the pairwise PLA results in Fig. 7 , it is likely that the differences in percentage of cells or red spots/cell shown would account for a maximum difference of 10 % in the expression of triple complexes in AD versus wild-type mice. Remarkably, the evidence of marked D 1 -H 3 -NMDA receptor complex expression in mice exhibiting an accelerated AD phenotype due to overexpression of the human amyloid precursor protein make these complexes attractive to combat amyloid-related excitotoxic damage. The increased excitotoxic vulnerability by amyloid protein [39] and evidence of Aß binding to NMDA receptors [5, 40, 41] , prompted the assay of Aß toxicity that was also prevented by thioperamide. Taken together, the results indicate a neuroprotective potential of H 3 receptor antagonists.
Passaia and Blandina [42] reviewed data suggesting modulation by histamine via H 3 receptors of cholinergic tone in the cortex and hippocampus and proposed the use of thioperamide as a potential pharmacological intervention to enhance cholinergic input in AD. To our knowledge, thioperamide has not been tested in AD animal models. However, recently released results from a 16-week phase II clinical trial in subjects with mild-to-moderate AD [43] show that a monotherapy with GSK239512, a safe and brainpenetrant selective H 3 receptor antagonist, improves episodic but not working memory or executive functions. Although the cognitive effects were virtually absent in these patients, the potential of H 3 receptor antagonists to prevent disease progression may not be underestimated, and our in vitro results show that H 3 receptor antagonism is very efficacious in preventing excitotoxicity and Aß peptide toxicity. What the results suggest is that H 3 receptor antagonists may not be 
